RenovoRx, Inc.

NASDAQ:RNXT

Biotechnology

Healthcare
$1.12 -0.86%

-$0.01 today

Market cap
$54.04M
Beta
0.99
P/E (TTM)
-3.4
EPS (TTM)
-$0.32
52W Low $0.70High $1.45

Volume 0.84M

Average 0.29M

RNXT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

RenovoRx, Inc.NASDAQ: RNXT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 85.1%

Gross margin was 85.1% in Q1 FY2026, up 32.8 pp from a year earlier. On a trailing-twelve-month basis it was 78.7%, up 17.9 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
85.1%-3.2 pp QoQ
Last fiscal yearDec 2025
70.9%-29.1 pp YoY
LTMMar 2026
78.7%+17.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+32.8 pp——
1 year-29.1 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
70.9%
Year-over-year change
-29.1pp

Gross Margin vs competitors

How RNXT compares with its peers on the latest reported figures

  • RNXT's LTM Mar 2026 gross margin of 78.7% is the highest of the 2 companies compared; the peer median is 76.0%.
  • Its year-over-year change of +17.9 pp is the highest of 2, against a peer median of +3.7 pp.
RNXT Competitors Peer median
Gross Margin for RNXT and competitors
Company Period LTM level YoY 3-year change
RNXTRenovoRx, Inc.LTM Mar 202678.7% +17.9 pp—
CELUCelularity Inc.LTM Dec 202576.0% +3.7 pp+85.4 pp
PYPDPolyPid Ltd.FY2025— ——
MAIAMAIA Biotechnology, Inc.FY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
LTRNLantern Pharma Inc.FY2025— ——
Peer median (excluding RNXT) 76.0%+3.7 pp+85.4 pp

Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00043K1.12M
Cost of Revenue0000327K
Gross Profit00043K796K
Gross Margin———100.0%70.9%
Research & Development3.04M4.3M5.67M6.03M6.27M
Selling, General & Admin2.63M5.65M5.73M4.99M7.04M
Operating Expenses5.67M9.95M11.4M11.01M13.31M
Depreciation & Amortization9K6K6K02K
EBITDA(5.48M)(9.83M)(10.12M)(8.81M)(11.17M)
EBITDA Margin———-20497.7%-994.3%
Operating Income(5.67M)(9.95M)(11.4M)(10.97M)(12.51M)
Operating Margin———-25511.6%-1114.0%
Interest Income70K57K0384K427K
Interest Expense904K57K108K00
Other Income / Expenses(653K)61K1.16M2.16M1.34M
Income Before Tax(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Pre-Tax Margin———-20497.7%-994.5%
Income Tax Expense00000
Net Income(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Net Margin———-20497.7%-994.5%
EPS (Basic)(0.40)(0.54)(0.50)(0.37)(0.32)
EPS (Diluted)(0.40)(0.54)(0.50)(0.37)(0.32)
Weighted Avg Shares17.87M18.1M20.58M23.61M35.33M
Weighted Avg Shares (Diluted)17.87M18.1M20.58M23.61M35.33M

RenovoRx, Inc.

NASDAQ:RNXT

Intrinsic Alpha fair value

Locked

Current Price

$1.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.